Product image of Ondansetron Accord (Ondansetron) supplied by GNH India

Ondansetron Accord

Active Ingredient:
Ondansetron
Origin:
EU

Ondansetron Accord (Ondansetron)

Ondansetron, the active ingredient in Ondansetron Accord, is a 5-HT3 receptor antagonist presented as a 4 mg oral tablet for systemic use. It helps prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult patients.

GNH India supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ondansetron Accord is a selective 5‑HT3 receptor antagonist used across several emesis‑related pathways.

  • Chemotherapy‑induced nausea and vomiting (CINV): reduces the frequency and severity of acute and delayed episodes.
  • Radiotherapy‑induced nausea and vomiting (RINV): helps control nausea during and after radiation treatment.
  • Post‑operative nausea and vomiting (PONV): lowers the incidence of nausea and vomiting after surgical procedures.

How It Works

  • Ondansetron blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting this receptor, it prevents serotonin‑mediated stimulation of the vomiting centre, thereby reducing nausea and vomiting signals.

Side Effects

Side effects reported with ondansetron are generally mild to moderate and vary by individual.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Constipation: occasional bowel movement difficulty.
  • Diarrhoea: loose stools in a minority of patients.
  • Fatigue: feeling of tiredness or reduced energy.
  • Dizziness: transient light‑headed sensations.

Serious or Rare Side Effects

  • Cardiac arrhythmia: QT‑interval prolongation, especially with high intravenous doses.
  • Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
  • Serotonin syndrome: rare when combined with other serotonergic agents.
  • Hepatic enzyme elevation: abnormal liver function tests in isolated cases.

Precautions & Warnings

When prescribing Ondansetron Accord, clinicians should consider several safety aspects.

  • Cardiac monitoring: assess baseline ECG in patients with known cardiac disease or electrolyte imbalance.
  • Electrolyte balance: correct hypokalaemia or hypomagnesaemia before use.
  • Drug interactions: review concomitant medications that may affect QT interval.
  • Pregnancy: use only if the potential benefit outweighs risk; data are limited.
  • Breastfeeding: limited data, weigh benefits against possible infant exposure.
  • Store at below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Ondansetron may interact with several medicines that influence cardiac rhythm or serotonergic pathways.

Major Interactions (Avoid)

  • Class I anti‑arrhythmic agents (e.g., quinidine, procainamide): increase risk of QT prolongation.
  • Certain antifungal agents (e.g., ketoconazole, itraconazole): potentiate QT prolongation.
  • Serotonergic drugs (e.g., tramadol, linezolid, SSRIs): raise the risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

  • Macrolide antibiotics (e.g., erythromycin, azithromycin): may modestly extend QT interval.
  • Certain antipsychotics (e.g., haloperidol, ziprasidone): additive effect on cardiac repolarisation.
  • Calcium channel blockers (e.g., amlodipine, verapamil): can affect ondansetron metabolism.

Frequently Asked Questions

Ondansetron Accord is a generic formulation of ondansetron that is used to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy and surgery. It is prescribed for adult patients who are at risk of emesis related to these medical procedures.

Ondansetron works by selectively blocking serotonin type‑3 (5‑HT3) receptors in the gastrointestinal tract and the brain’s chemoreceptor trigger zone. This inhibition stops serotonin‑driven signals from activating the vomiting centre, thereby reducing the sensation of nausea and the act of vomiting.

The dose of Ondansetron Accord is determined by the prescribing clinician based on the indication, patient weight, renal function and other clinical factors. Healthcare professionals set the appropriate strength and dosing schedule for each individual case.

Safety data for ondansetron in pregnancy are limited, so it should only be used when the potential benefit justifies any possible risk to the fetus. Limited information is available for breastfeeding; the decision should balance maternal benefit against potential infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, which is generally more effective for acute chemotherapy‑induced nausea than dopamine antagonists such as metoclopramide. It has a favorable side‑effect profile, though both classes share risks of constipation and headache.

Ondansetron Accord should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Maintaining these conditions helps preserve the tablet’s potency and stability throughout its shelf life.

The medication is supplied as an oral tablet that is swallowed whole with water. Depending on the clinical situation, it may be taken shortly before chemotherapy, radiotherapy or surgery, as directed by the treating physician.

Serious risks include cardiac arrhythmias such as QT‑interval prolongation, especially in patients with existing heart disease or electrolyte disturbances, and rare cases of severe allergic reactions. Prompt medical attention is required if symptoms like palpitations, fainting or rash develop.

Patients with known hypersensitivity to ondansetron or any component of the tablet should avoid it. Caution is also advised for individuals with congenital long‑QT syndrome, uncontrolled electrolyte imbalances, or those taking other QT‑prolonging drugs.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ondansetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT